154 related articles for article (PubMed ID: 26704932)
21. Truncated E-cadherin potentiates cell death in prostate epithelial cells.
Rios-Doria J; Day ML
Prostate; 2005 May; 63(3):259-68. PubMed ID: 15538719
[TBL] [Abstract][Full Text] [Related]
22. [Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer].
Liu WT; Jiao HL; Yang YL; Wang D; Zhang WM
Ai Zheng; 2007 Nov; 26(11):1199-203. PubMed ID: 17991318
[TBL] [Abstract][Full Text] [Related]
23. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
24. Posttranslational truncation of E-cadherin and significance for tumour progression.
Masterson J; O'Dea S
Cells Tissues Organs; 2007; 185(1-3):175-9. PubMed ID: 17587823
[TBL] [Abstract][Full Text] [Related]
25. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells.
Shtutman M; Levina E; Ohouo P; Baig M; Roninson IB
Cancer Res; 2006 Dec; 66(23):11370-80. PubMed ID: 17145883
[TBL] [Abstract][Full Text] [Related]
26. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?
Jeanes A; Gottardi CJ; Yap AS
Oncogene; 2008 Nov; 27(55):6920-9. PubMed ID: 19029934
[TBL] [Abstract][Full Text] [Related]
27. Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer.
Yu Z; Sun M; Jin F; Xiao Q; He M; Wu H; Ren J; Zhao L; Zhao H; Yao W; Shan F; Cao Y; Wei M
Oncol Rep; 2015 Jul; 34(1):165-74. PubMed ID: 25955302
[TBL] [Abstract][Full Text] [Related]
28. Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes.
Bajenova O; Chaika N; Tolkunova E; Davydov-Sinitsyn A; Gapon S; Thomas P; O'Brien S
Exp Cell Res; 2014 Jun; 324(2):115-23. PubMed ID: 24726916
[TBL] [Abstract][Full Text] [Related]
29. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface.
Tang MKS; Yue PYK; Ip PP; Huang RL; Lai HC; Cheung ANY; Tse KY; Ngan HYS; Wong AST
Nat Commun; 2018 Jun; 9(1):2270. PubMed ID: 29891938
[TBL] [Abstract][Full Text] [Related]
30. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.
Clapéron A; Mergey M; Nguyen Ho-Bouldoires TH; Vignjevic D; Wendum D; Chrétien Y; Merabtene F; Frazao A; Paradis V; Housset C; Guedj N; Fouassier L
J Hepatol; 2014 Aug; 61(2):325-32. PubMed ID: 24704591
[TBL] [Abstract][Full Text] [Related]
31. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.
Chang YW; Marlin JW; Chance TW; Jakobi R
Cancer Res; 2006 Dec; 66(24):11700-8. PubMed ID: 17178865
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of E-cadherin dependent cell-cell contact promotes MUC5AC mucin production through the activation of epidermal growth factor receptors.
Iwashita J; Ose K; Ito H; Murata J; Abe T
Biosci Biotechnol Biochem; 2011; 75(4):688-93. PubMed ID: 21512244
[TBL] [Abstract][Full Text] [Related]
33. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression.
Wu C; Cipollone J; Maines-Bandiera S; Tan C; Karsan A; Auersperg N; Roskelley CD
Differentiation; 2008 Feb; 76(2):193-205. PubMed ID: 17608733
[TBL] [Abstract][Full Text] [Related]
34. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
35. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.
Zhong XY; Zhang LH; Jia SQ; Shi T; Niu ZJ; Du H; Zhang GG; Hu Y; Lu AP; Li JY; Ji JF
Histopathology; 2008 Apr; 52(5):560-8. PubMed ID: 18312357
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition.
Lin YC; Lee YC; Li LH; Cheng CJ; Yang RB
J Cell Sci; 2014 Jan; 127(Pt 1):85-100. PubMed ID: 24213532
[TBL] [Abstract][Full Text] [Related]
37. T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
Kyriakakis E; Maslova K; Philippova M; Pfaff D; Joshi MB; Buechner SA; Erne P; Resink TJ
J Invest Dermatol; 2012 Sep; 132(9):2275-85. PubMed ID: 22592160
[TBL] [Abstract][Full Text] [Related]
38. P-cadherin role in normal breast development and cancer.
Albergaria A; Ribeiro AS; Vieira AF; Sousa B; Nobre AR; Seruca R; Schmitt F; Paredes J
Int J Dev Biol; 2011; 55(7-9):811-22. PubMed ID: 22161837
[TBL] [Abstract][Full Text] [Related]
39. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
Bremm A; Walch A; Fuchs M; Mages J; Duyster J; Keller G; Hermannstädter C; Becker KF; Rauser S; Langer R; von Weyhern CH; Höfler H; Luber B
Cancer Res; 2008 Feb; 68(3):707-14. PubMed ID: 18245470
[TBL] [Abstract][Full Text] [Related]
40. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1.
Noë V; Fingleton B; Jacobs K; Crawford HC; Vermeulen S; Steelant W; Bruyneel E; Matrisian LM; Mareel M
J Cell Sci; 2001 Jan; 114(Pt 1):111-118. PubMed ID: 11112695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
